In vivo efficacy in airway disease models of N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl] -glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration

Journal of Pharmacology and Experimental Therapeutics

Volumn 307, Issue 1, 2003, Pages 373-385

  Kuss, Hildegard ^a,b   Hoefgen, N ^a   Johanssen, S ^a   Kronbach, T ^a   Rundfeldt, C ^a  

^a Elbion AG   (Germany)

^b Elbion AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BECLOMETASONE; CILOMILAST; DEXAMETHASONE; LIPOPOLYSACCHARIDE; N (3,5 DICHLORO 4 PYRIDYL) [1 (4 FLUOROBENZYL) 5 HYDROXY 3 INDOLYL]GLYOXYLIC ACID AMIDE; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; STEROID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHODILATATION; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CELL INFILTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EOSINOPHILIA; FERRET; LUNG LAVAGE; NEUTROPHILIA; NONHUMAN; PRIORITY JOURNAL; RAT STRAIN; RESPIRATORY TRACT DISEASE; SENSITIZATION; SWINE; VOMITING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADMINISTRATION, INHALATION; ALLERGENS; AMIDES; ANIMALS; BRONCHOCONSTRICTION; DOGS; EOSINOPHILIA; FERRETS; GUINEA PIGS; INDOLES; LIPOPOLYSACCHARIDES; LUNG DISEASES; MICE; NEUTROPHILS; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, INBRED LEW; SWINE; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 0141630489     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.053942     Document Type: Article

References (43)

1. Andersson P (1980) Antigen-induced bronchial anaphylaxis in actively sensitized guinea pigs. Allergy 35:65-71.
2. Ashton MJ, Cook DC, Fenton G, Karlsson JA, Palfreyman MN, Raeburn D, Ratcliffe AJ, Souness JE, Thurairaitnam S, and Vicker N (1994) Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-cyclopentyloxy-4-methoxybenzamides and analogues. J Med Chem 37:1696-1703.
3. Barnes PJ (1999) Therapeutic strategies for allergic diseases. Nature (Lond) 402: B31-B38.
4. Barnes PJ (2000) Chronic obstructive pulmonary disease. N Engl J Med 343:269-280.
5. Barnette MS (1999) Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD), in Progress in Drug Research (Jucker E ed) vol 53, Birkhäuser, Basel, Switzerland.
6. Barnette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, Kagey-Sobotka A, and Torphy TJ (1998) SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther 284:420-426.
7. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, and Beume R (2001) In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 297:280-290.
8. Burnouf C and Pruniaux M-P (2002) Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des 8:1255-1296.
9. Compton CH, Gubb J, Nieman R et al. (2001) Cilomilast, a selective phosphodiesterase 4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358:265-270.
10. Dale TJ, Ball DI, Nials AT, and Coleman RA (1995) The anti-inflammatory and emetogenic effects of phosphodiesterase (PDE) IV inhibitors in conscious ferrets. Br J Pharmacol 116:91P
11. Djukanovic R, Roche WR, Wilson JW, Beasley CR, Twentyman OP, Howarth RH, and Holgate ST (1990) Mucosal inflammation in asthma. Am Rev Respir Dis 142:434-457.
12. Eum S-Y, Haile S, Lefort J, Huerre M, and Vargaftig BB (1995) Eosinophil recruitment into the respiratory epithelium following antigenic challenge in hyper-IgE mice is accompanied by interleukin 5-dependent bronchial hyperresponsiveness. Proc Natl Acad Sci USA 92:12290-12294.
13. Gasparic A, Schupke H, Olbrich M, Krone D, Peter G, Hempel R, and Kronbach T (2002) O-Glucoronidation as major metabolic pathway of the phosphodiesterase 4 inhibitor AWD 12-281 in vitro and in vivo. Abstract book of the 18th European Workshop on Drug Metabolism, Sept. 16-20, 2002; Valencia, Spain.
14. Hatzelmann A and Schudt C (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297:267-279.
15. Hoefgen N, Polymeropoulos E, Egerland U, Poppe H, Marx D, Kronbach T, and Szelenyi S (1999) AWD 12-281, a new PDE 4 inhibitor created by ligand based drug design. Mediators Inflamm 8 (Suppl 1):104.
16. Howell RE, Jenkins LP, Fielding LE, and Grimes D (1995) Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats. Pulm Pharmacol 8:83-89.
17. Kuesters S, Marx D, Roellig H, Rudert J, and Szelenyi I (1999) AWD 12-281, a new potent PDE4 inhibitor: in vitro activity and effect on bronchial hyperreactivity (BHR) in BP-2 mice. Am J Respir Crit Care Med 159 (Suppl):A114.
18. Kuss H, Höefgen N, Egerland U, Heer S, Marx D, Szelenyi I, Schupke H, Gasparic A, Olbrich M, Hempel R, et al. (2002a) AWD 12-281: antiasthmatic/antiinflammatory phosphodiesterase 4 inhibitor. Drugs Future 27:111-116.
19. Kuss H, Höefgen N, and Rundfeldt C (2002b) AWD 12-281, a new selective PDE4-inhibitor with a high safety margin: separation of anti-inflammatory and emetic effects in ferrets and domestic pigs. Eur Respir J 20 (Suppl 38):617s.
20. Kuss H, Höefgen N, and Rundfeldt C (2002c) Late phase eosinophilia as an animal model of asthma: effects and time course of the selective PDE4-inhibitor AWD 12-281 in guinea pigs and Brown Norway rats. Naunyn-Schmiedeberg's Arch Pharmacol 365 (Suppl):R100.
21. Kuss H, Kasper M, Höefgen N, and Rundfeldt C (2002d) Inhibition of late phase eosinophilia in allergen challenged Brown Norway rats by AWD 12-281, a new selective PDE4-inhibitor and local tolerability in rat lungs. Am J Respir Crit Care Med 165 (Suppl):A185.
22. Leichtl S, Seyd J, Bredenbröker D, Rathgeb F, and Wurst W (2002) Efficacy of once daily roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 165 (Suppl): A229.
23. Marx D, Poppe H, and Szelenyi I (1999) The in vivo activity of AWD 12-281, a potent PDE4 inhibitor for the treatment of allergic asthma. J Allergy Clin Immunol 103 (Suppl):S127.
24. Marx D, Tassabehji M, Heer S, Hüttenbrink K-B, and Szelenyi I (2002) Review: modulation of TNF and GM-CSF release from dispersed human nasal polyp cells and human whole blood by inhibitors of different PDE isoenzymes and glucocorticoids. Pulm Pharmacol Ther 15:7-15.
25. Payne AN and De Nucci G (1987) Anaphylaxis in guinea pigs induced by ovalbumin aerosol in vivo and in vitro methods. J Pharmacol Methods 17:83-90.
26. Poppe H, Heer S, Sims G, Höefgen N, and Szelenyi I (2001a) Effects of selective PDE4-inhibitors and β2-agonists on tracheal phenol red secretion in mice and LPS-induced TNFα release in human blood. Naunyn-Schmiedeberg's Arch Pharmacol 363 (Suppl):R111.
27. Poppe H, Höefgen N, and Szelenyi I (2000a) Effect of new selective PDE4-inhibitors AWD 12-281 and AWD 12-343 in comparison with SB 207499 and rolipram on LPS-induced neutrophilia in Lewis rat lung, an animal model of COPD. Naunyn-Schmiedeberg's Arch Pharmacol 361 (Suppl):R118.
28. Poppe H, Kuesters S, and Szelenyi I (1999) Effect of AWD 12-281, a new selective PDE4-inhibitor, loteprednol and beclomethasone in models of allergic rhinitis and airway inflammation in Brown Norway-rats. Am J Respir Crit Care Med 159 (Suppl):A95.
29. Poppe H, Marx D, Heer S, Egerland U, Höefgen N, and Szelenyi I (2001b) Effects of a selective PDE4-inhibitor AWD 12-281 in comparison with SB 207499 and roflumilast on tracheal phenol red secretion in mice and LPS-induced neutrophilia in BAL in Lewis rats and domestic pigs. Am J Respir Crit Care Med 163 (Suppl): A994.
30. Poppe H, Marx D, and Szelenyi I (2000b) The in vivo activity of AWD 12-281, a potent phosphodiesterase 4 (PDE4) inhibitor for the treatment of allergic asthma and COPD. Allergy 55 (Suppl 63):968.
31. Poppe H, Sims G, Helm K-P, and Rundfeldt C (2001c) The selective PDE4-inhibitor AWD 12-281 inhibits LPS-induced neutrophilia in domestic pig lung, an animal model of COPD: comparison with steroids. Eur Respir J 18 (Suppl 33):160s.
32. Poppe H and Szelenyi I (1999) Effect of the new selective PDE4-inhibitor AWD 12-281 and RPR 73401 on LPS-induced neutrophilia in ferret lung and emetogenic effects in conscious ferrets. Naunyn-Schmiedeberg's Arch Pharmacol 359 (Suppl): R114.
33. Poppe H, Tschernig T, Hanke M, Pabst R, and Szelenyi I (2000c) Comparison of a new selective PDE4-Inhibitor AWD 12-281 with budesonide on lymphocyte entry and eosinophilia in the bronchoalveolar space of the Brown Norway rat. Am J Respir Crit Care Med 161 (Suppl):A184.
34. Raeburn D, Underwood SL, Lewis SA, Woodman VR, Battram CH, Tomkinson A, Sharma S, Jordan R, Souness JE, Webber SE, et al. (1994) Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol 113:1423-1431.
35. Schmidt D, Dent G, and Rabe KF (1999) Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 29:99-109.
36. Shenkar R and Abraham E (1999) Mechanisms of lung neutrophil activation after haemorrhage or endotoxemia: roles of reactive oxygen intermediates, NF-κB and cyclic AMP response element binding protein. Am Assoc Immunol 163:954-962.
37. Spond J, Chapman R, Fine J, Jones H, Kreutner W, Kung TT, and Minnicozzi M (2001) Comparison of PDE4 inhibitors, rolipram and SB 207499 (Ariflo™), in a rat model of pulmonary neutrophilia. Pulm Pharmacol Ther 14:157-164.
38. Tarayre JP, Aliaga M, Barbara M, Tisseyre N, Vieu S, and Tisne-Versailles J (1992) Model of bronchial allergic inflammation in the brown Norway rat. Pharmacological modulation. Int J Immunopharmacol 14:847-855.
39. Torphy TJ (1998) Phosphodiesterase isoenzymes, molecular targets for novel anti-asthma agents. Am J Respir Crit Care Med 157:351-370.
40. Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, Nieman RB, and Compton CH (1999) Ariflo(™) (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 12:131-135.
41. Underwood DC, Bochnowicz S, Osborn RR, Hay DWP, and Torphy TJ (1998) The therapeutic activity of SB 207499 (Ariflo™), a second generation phosphodiesterase 4 (PDE4) inhibitor, is equivalent to that of prednisolone in models of pulmonary inflammation. Am J Respir Crit Care Med 157 (Suppl):A872.
42. Underwood DC, Matthews JK, Osborn RR, Bochnowicz S, and Torphy TJ (1997) The influence of endogenous catecholamines on the inhibitory effects of rolipram against early- and late-phase response to antigen in the guinea pig. J Pharmacol Exp Ther 280:210-219.
43. Underwood DC, Osborn RR, Novak LB, Matthews JK, Newsholme SJ, Undem BJ, Hand JM, and Torphy TJ (1993) Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J Pharmacol Exp Ther 266:306-313.